Get access

Distant metastases from cutaneous squamous cell carcinoma—analysis of AJCC stage IV

Authors

  • Markus Brunner MD,

    Corresponding author
    1. Sydney Head and Neck Cancer Institute, The Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, 2050, Sydney, Australia
    • Sydney Head and Neck Cancer Institute, The Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, 2050, Sydney, Australia
    Search for more papers by this author
  • Michael J. Veness MMed, MD, FRANZCR,

    1. Head and Neck Cancer Service, Westmead Hospital, University of Sydney, Sydney, Australia
    Search for more papers by this author
  • Sydney Ch'ng MBBS, FRACS (PLAST),

    1. Sydney Head and Neck Cancer Institute, The Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, 2050, Sydney, Australia
    Search for more papers by this author
  • Michael Elliott FRACS,

    1. Sydney Head and Neck Cancer Institute, The Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, 2050, Sydney, Australia
    2. Sydney Medical School, University of Sydney, Australia
    Search for more papers by this author
  • Jonathan R. Clark MBBS(Hons)

    1. Sydney Head and Neck Cancer Institute, The Sydney Cancer Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, 2050, Sydney, Australia
    Search for more papers by this author

Abstract

Background

The seventh edition of the American Joint Committee on Cancer (AJCC) Staging Manual introduced a more detailed system to stage regional lymph node metastases for disease with cutaneous squamous cell carcinoma (SCC). The purpose of this study was to determine if the inclusion of disease staged N2 and N3 together with disease staged M1 is an appropriate grouping within stage IV.

Methods

A retrospective multicenter analysis was conducted of 603 patients with metastatic cutaneous SCC to compare survival data for regional (N2 and N3) versus distant metastases.

Results

Disease specific survival (DSS) and overall survival (OS) were much poorer for patients with distant disease compared to those with different stages of regional disease. After 5 years, only 25% of patients with N2 disease and 35% of patients with N3 disease died from their cancer compared with 89% of patients with distant metastases.

Conclusion

Our results indicate that in cutaneous SCC, stage IV represents a very heterogeneous group. Therefore, N2 and N3 disease should not be grouped with M1 together within AJCC stage IV. © 2012 Wiley Periodicals, Inc. Head Neck, 2013

Ancillary